A Phase I/II Clinical Study of SHR-1681 for Injection in Patients With Advanced Solid Tumors
This study is an open-label, multicenter Phase I/II clinical trial to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-1681 for injection in patients with advanced solid tumors.
Malignant Solid Tumors
DRUG: SHR-1681
Maximum tolerated dose (MTD), 12 months.|Maximum administered dose (MAD), 12 months.|Recommended Phase 2 dose (RP2D), 12 months.|Incidence and severity of adverse events (AEs), Approximately 3 years.|Incidence and severity of serious adverse events (SAEs), Approximately 3 years.
Time to maximum concentration (Tmax) of SHR-1681, Approximately 3 years.|Maximum concentration (Cmax) of SHR-1681, Approximately 3 years.|Area under the concentration-time curve from time 0 to the last measurable concentration time point (AUC0-t) of SHR-1681, Approximately 3 years.|Area under the concentration-time curve from time 0 to infinity (AUC0-âˆž) of SHR-1681, Approximately 3 years.|Anti-SHR-1681 antibody (ADA) of SHR-1681, Approximately 3 years.|Overall response rate (ORR), Approximately 3 years.|Duration of response (DoR), Approximately 3 years.|Disease control rate (DCR), Approximately 3 years.|Progression-free survival (PFS), Approximately 3 years.|Overall survival (OS), Approximately up to 5 years after the last subject enrolled.
This study is an open-label, multicenter Phase I/II clinical trial to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-1681 for injection in patients with advanced solid tumors.